# Alcohol Use Disorder FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/alcohol-use-disorder

> 4 upcoming FDA catalysts in alcohol Use Disorder: brenipatide (LLY) on April 2028 (primary completion); brenipatide (LLY) on Apr to Jul 2028 (topline data readout); brenipatide (LLY) on April 2028 (primary completion); brenipatide (LLY) on Apr to Jul 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 18, 2025 | [CMND-100 topline data readout](https://sec-api.dev/pdufa/cmnd-100) | CMND | Alcohol Use Disorder | completed, positive | "Canada, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced positive top-line results from the first cohort of its Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1892500/000121390025112114/ea026618401ex99-1_clearmind.htm)) |
| March 19, 2026 | [Mazdutide primary completion](https://sec-api.dev/pdufa/mazdutide) | LLY | Alcohol Use Disorder | completed | "NCT06817356 (A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-19 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06817356)) |
| April 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Alcohol Use Disorder | scheduled | "NCT07219953 (A Study of Brenipatide in Participants With Alcohol Use Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219953)) |
| Apr to Jul 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Alcohol Use Disorder | scheduled | "NCT07219953 (A Study of Brenipatide in Participants With Alcohol Use Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219953)) |
| April 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Alcohol Use Disorder | scheduled | "NCT07219966 (A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219966)) |
| Apr to Jul 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Alcohol Use Disorder | scheduled | "NCT07219966 (A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219966)) |

## Drugs

- [CMND-100](https://sec-api.dev/pdufa/cmnd-100) (CMND)
- [Mazdutide](https://sec-api.dev/pdufa/mazdutide) (LLY)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/alcohol-use-disorder.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Alcohol Use Disorder FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/alcohol-use-disorder

```bibtex
@misc{secapidev_indications_alcohol_use_disorder_20261116,
  title        = {Alcohol Use Disorder FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/alcohol-use-disorder}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_alcohol_use_disorder_20261116","title":"Alcohol Use Disorder FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/alcohol-use-disorder","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
